Clinical Predictors of Fatigue in Men With Non-Metastatic Prostate Cancer Receiving External Beam Radiation Therapy

Li Feng

Mei-kuang Chen

Nada Lukkahatai

Chao-Pin Hsiao

Aradhana Kaushal

Lee Sechrest

Leorey N. Saligan

cancer-related fatigue, anemia, radiation therapy, prostate cancer
CJON 2015, 19(6), 744-750. DOI: 10.1188/15.CJON.744-750

Background: Fatigue is one of the most distressing symptoms experienced by people with cancer receiving radiation therapy.

Objectives: The goal of this study is to evaluate clinical predictors of worsening fatigue during external beam radiation therapy (EBRT) in men with non-metastatic prostate cancer.

Methods: Thirty-five men with non-metastatic prostate cancer scheduled for EBRT were followed at baseline, midpoint, and completion of EBRT. The Functional Assessment of Cancer Therapy–Fatigue scale was administered. Demographic and clinical data were obtained by chart review. Paired t-tests, correlations, general linear models, and logistic regressions were used to determine associations between fatigue scores and clinical data.

Findings: Red blood cells, hemoglobin, and hematocrit levels were highly intercorrelated and, therefore, were grouped as one composite variable termed heme. Heme levels at baseline and androgen-deprivation therapy (ADT) were significantly correlated with worsening of fatigue symptoms from baseline to midpoint and endpoint. ADT alone did not have a significant correlation with fatigue, but it indirectly affected fatigue levels by influencing heme markers as treatment progressed. These findings provide evidence that hematologic markers and the use of ADT assist in predicting radiation therapy-related fatigue and guide symptom management.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.